Citations 1
A Randomized Trial Comparing Inhaled Insulin Plus Basal Insulin Versus Usual Care in Adults With Type 1 Diabetes
Hirsch, Irl B. , Beck, Roy W. , Marak, Martin Chase , Kudva, Yogish C. , Aktürk, Halis Kaan , Bhargava, Anuj , Codorniz, Kevin , Diner, Jamie, Aleppo, Grazia , Blevins, Thomas , Raskin, Philip, Castorino, Kristin , Manessis, Anastasios , Pickering, David, Weinstock, Ruth S. , Bode, Bruce W. , Nguyen, Quang T., Kipnes, Mark, Ruedy, Katrina J., Desjardins, Donna, Haider, Zehra, Jacobson, Christopher , Klein, Klara R. , O’Malley, Grenye , Church, Mei Mei , Mottalib, Adham , Baran, Jesica D., Kurek, Corey, Rizvi, Shafaq, Donahue, Cassandra, Tamarez, Denisa, Atakov-Castillo, Astrid , Borgman, Sarah, Frey, Sarah, Calhoun, Peter , Group, INHALE-3 Study, Ownby, Jonathan G., Johnson, Joseph H., Ruiz, Adriana, Stephens, Nashia, Maxson, Amanda, Akturk, Halis K., Beatson, Christie , Mason, E E , Wolpert, Howard , Sullivan, Asya, Salhin, Amna, Copple, Tina, Beltran, Stephanie, Ryan, Terri, Levister, Camilla, Ipek, Aslihan, Burke, Christine, Langel, Christine, Bauman, Shannon , Haight, Cristina, Bohr, A., Mottalib, Adham, Salah, Tareq , Badri, Marwa Al, Nguyen, Quang T., Nguyen, Loida, Cordero, Christian, Migliozzi, Brittney, Reid, Corey, Kaur, Ravinder Jeet , Livingood, Daine, Cruse, Dana, Kravarusic, Jelena, Coyne, Kasey, Herrmann, Stefanie, Fronczyk, Evelyn, Manessis, Anastasios, McKillop, Lorcan, Hyatt, Jamie, Patruno, Maria, Castorino, Kristin, Church, Mei Mei, Thorsell, Ashley, Shuirman, Maggie, Cobb, Brandon, Watt, Olivia, Bzdick, Suzan, Casaubon, Luis, Espinosa, Valerie, Pandit, Keta, Perez, Jennifer, Armstrong, Chloe, Martinez-Arredondo, Maritza, Stewart, Ana, Ghorbani, Tahereh, Young, Laura , Donahue, Cassandra, Kass, Alexander, Fulghum, Karla, Raskin, Philip, Jordan, Lin, Shao, Baomei, Hirsch, Irl B., Baran, Jesica, Mandava, Patali, Holod, Rosanna, Kaiserman, Kevin B. , Ulloa, Johanna, Pleitez, Jennifer, Sylvan, Joey, Badgett, Lynn, Frey, Sarah, Mba-Oduwusi, Nnenna, Miller, Paige , Fults, Ashleigh, Pritchard, Rosa, Dolzhenko, E. N. , Gabrielson, Deanna, Brown, Sue A. , Ahmann, Andrew , Bergenstal, Richard M. , Kudva, Yogish C. , Akturk, Halis K , Levy, Carol J , Castorino, Kristin , Steenkamp, Devin W , Weinstock, Ruth S , Hamdy, Osama , Klein, Klara R , Church, Mei Mei , Mottalib, Adham , Calhoun, Peter , Hirsch, Irl B , Aleppo, Grazia , Beck, Roy W , Levy, Carol J. , Nguyen, Quang T., Lee, Scott Jeffery , Buse, John B. , Donahue, Cassandra, Borgman, Sarah, Calhoun, Peter , Group, INHALE-3 Study, Akturk, Halis K., Mason, Emma, Bauman, Shannon, Mottalib, Adham, Dhaver, Shilton , Nguyen, Quang T., Manessis, Anastasios, Castorino, Kristin, Church, Mei Mei, Johnson, Olivia, Coviello, Andrea D. , Donahue, Cassandra, Raskin, Philip, Hirsch, Irl B., Ulloa, Johanna, Frey, Sarah, Miller, Paige, McCarthy, Chris
Diabetes Care | December 6, 2024 | Volume: 48 | Issue: 3 | Pages: 353-360
OBJECTIVE To evaluate a regimen of inhaled Technosphere insulin (TI) plus insulin degludec in adults with type 1 diabetes, who prestudy were predominately using either an automated insulin delivery (AID) system or multiple daily insulin injections (MDI) with continuous glucose monitoring. RESEARCH DESIGN AND METHODS At 19 sites, adults with type 1 diabetes were randomly assigned to TI plus insulin degludec (N = 62) or usual care (UC) with continuation of prestudy insulin delivery method (N = 61) for 17 weeks. RESULTS Prestudy, AID was used by 48% and MDI by 45%. Mean ± SD HbA1c was 7.57% ± 0.97% at baseline and 7.62% ± 1.06% at 17 weeks in the TI group and 7.59% ± 0.80% and 7.54% ± 0.77%, respectively, in the UC group (adjusted difference 0.11%, 95% CI −0.10 to 0.33, P value for noninferiority = 0.01). HbA1c improved from baseline to 17 weeks by >0.5% (5.5 mmol/mol) in 12 (21%) in the TI group and in 3 (5%) in the UC group and worsened by >0.5% (5.5 mmol/mol) in 15 (26%) in the TI group and in 2 (3%) in the UC group. The most common TI side effect was a brief cough; eight participants discontinued TI due to side effects. CONCLUSIONS In adults with type 1 diabetes, HbA1c after 17 weeks with a regimen of TI and degludec was noninferior to UC, which consisted predominately of either AID or MDI. TI should be considered an option for people with type 1 diabetes, particularly those who are motivated to further reduce postprandial hyperglycemia.